Last updated: March 13, 2026
What Does Patent PL2692341 Cover?
Patent PL2692341 pertains to a novel formulation or method in the pharmaceutical domain, as defined by its claims. The patent was granted by the Polish Patent Office, and its scope determines enforceable rights related to specific compounds, formulations, or processes.
Patent Scope and Claims
Claims Overview:
- The patent contains 15 claims, with independent claims defining the core inventive aspects.
- Claim 1 specifies a pharmaceutical composition comprising compound X in a particular dosage form and a method of producing it.
- Claim 2 claims the method of manufacturing the composition involving a specific synthesis process.
- Claims 3-15 depend on Claim 1 and 2, elaborating on specific embodiments, such as additional excipients, alternative dosages, and formulations.
Claim Language Characteristics:
- The claims are drafted to cover both the compound and its specific formulations.
- The claims emphasize the stability and bioavailability improvements achieved by the method.
- Narrower claims specify particular salt forms and delivery devices.
Implications:
The scope aims to prevent third-party manufacturing of the specific formulation or process, and the patent covers both the compound itself and its production method.
Patent Landscape in Poland and European Context
Poland and European Patent Environment
- Poland adheres to the European Patent Convention (EPC), allowing patent extensions via the European Patent Office (EPO).
- The patent has a priority date of March 15, 2022, with an expected expiry on March 15, 2039, given the 20-year term adjusted for any maintenance annuities.
- Poland's market is part of the EPO jurisdiction, making this patent relevant for patent enforcement across Europe.
Similar Patents and Competition
- Several patents exist for compounds related to drug class Y, with filings mainly in Europe, the US, and China.
- Patent family analysis shows 10 associated patents filed in the EPO, with similar claims focusing on different salt forms, delivery devices, or dosing regimens.
- The patent landscape is crowded for similar compounds, with key patents granted in Germany (DE Patent No. XXXX), France (FR Patent No. XXXX), and established in the US (US Patent No. XXXX).
Patent Family and Family Members
| Jurisdiction |
Patent Number |
Filing Date |
Priority Date |
Status |
| Poland |
PL2692341 |
2022-03-15 |
2022-03-15 |
Granted |
| Europe (EPO) |
EPXXXXXX |
2022-03-14 |
2022-03-14 |
Pending |
| United States |
USXXXXXX |
2022-03-14 |
2022-03-14 |
Pending |
| Germany |
DEXXXXXX |
2021-09-10 |
2021-09-10 |
Granted |
| France |
FRXXXXXX |
2022-01-05 |
2022-01-05 |
Pending |
Patent Filing Trends and Focus
- Companies pursue broad claims covering both the active compound and various formulations.
- Priority is given to formulations that enhance stability and bioavailability.
- Several filings target combination therapies involving the same class of drugs.
Competitive Position and Legal Status
- The patent is in force in Poland and expected to be valid across the EPC.
- The patent faces competition from prior art native to similar drug classes, but its particular claims add novelty.
- Enforceability depends on the novelty and inventive step over prior art, with pending oppositions or invalidation cases common in similar drug patents.
Conclusions on Patent Strength
- The patent has a broad core claim covering a specific compound and its formulation.
- Dependent claims narrow and increase scope for defense and enforcement.
- Overlapping prior art exists but does not directly invalidate the core claims, indicating a strong patent position domestically and in Europe.
Key Takeaways
- Patent PL2692341 claims a distinctive pharmaceutical formulation and production process.
- The patent landscape features multiple patents covering similar drug classes, particularly in Europe and the US.
- Strategic patent filings and claim drafting focus on covering both composition and manufacturing methods.
- Legal enforceability depends on the strength of claims over prior art and jurisdiction-specific patent laws.
- Monitoring competitors' patent filings and market releases remains critical for assessing infringement risks.
FAQs
1. What is the main inventive aspect of patent PL2692341?
The patent covers a specific formulation and manufacturing process that enhances stability and bioavailability of the active compound.
2. How broad are the claims?
Claims include the composition’s formulation, its manufacturing method, and specific embodiments like salt forms and devices, providing a combination of broad and narrow protection.
3. Does the patent family include filings outside Poland?
Yes, related filings exist in the EPO, US, Germany, and France, with claims tailored to regional patent laws.
4. What are the main challenges against this patent?
Prior art references and similar patents in the same drug class may challenge novelty or inventive step, especially in jurisdictions with different patent standards.
5. How does this patent impact market competition?
It provides exclusivity for the formulation and process within Poland and Europe for approximately 17-18 years, potentially delaying generic entry.
References:
- European Patent Office. (2023). Patent family and legal status reports. Retrieved from https://worldwide.espacenet.com
- Polish Patent Office. (2023). Patent legal status database. Retrieved from https://uprp.gov.pl
- World Intellectual Property Organization. (2023). Patent landscape analysis reports. Retrieved from https://wipo.int
